Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective Publisher



Rezaee M1, 2 ; Karimzadeh I3 ; Hashemimeshkini A4 ; Zeighami S5 ; Bazyar M6 ; Lotfi F2 ; Keshavarz K2, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Fars, Shiraz, Iran
  2. 2. Health Human Resources Research Center, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Fars, Shiraz, Iran
  3. 3. Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Fars, Shiraz, Iran
  4. 4. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy and Evidence-Based Medicine Group, Tehran University of Medical Sciences, Tehran, Tehran, Iran
  5. 5. Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Fars, Shiraz, Iran
  6. 6. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Fars, Shiraz, Iran
  7. 7. Emergency Medicine Research Center, Shiraz University of Medical Sciences, Fars, Shiraz, Iran

Source: Value in Health Regional Issues Published:2024


Abstract

Objectives: Metastatic prostate cancer is the most common malignant cancer and the second leading cause of death due to various types of cancer among men after lung cancer. This study aimed to analyze the cost-effectiveness of triptorelin, goserelin, and leuprolide in the treatment of the patients with metastatic prostate cancer from the societal perspective in Iran in 2020. Methods: This is a cost-effectiveness study in which a 20-year Markov transition modeling was applied. In this study, local cost and quality-of-life data of each health state were gathered from cohort of patients. The TreeAge pro 2020 and Microsoft Excel 2016 software were used to simulate cost-effectiveness of each treatment in the long term. The one-way and probabilistic sensitivity analyses were also performed to measure robustness of the model outputs. Results: The findings indicated that the mean costs and utility gained over a 20-year horizon for goserelin, triptorelin, and leuprolide treatments were $ 13 539.13 and 6.365 quality-adjusted life-years (QALY), $ 18 124.75 and 6.658 QALY, and $ 26 006.92 and 6.856 QALY, respectively. Goserelin was considered as a superior treatment option, given the estimated incremental cost-effectiveness ratio. The one-way and probabilistic sensitivity analyses confirmed the robustness of the study outcomes. Conclusions: According to the results of the present study, goserelin was the most effective and cost-effective strategy versus 2 other options. It could be recommended to policy makers of the Iran healthcare system to prioritize it in clinical guidelines and reimbursement policies. © 2024 International Society for Health Economics and Outcomes Research
Related Docs
View other Related Docs
1. Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016, International Journal of Cancer Management (2023)
2. A Cost-Benefit Analysis of Mass Prostate Cancer Screening, Cost Effectiveness and Resource Allocation (2024)
3. Incidence and Mortality of Prostate Cancer and Their Relationship With the Human Development Index Worldwide, Prostate International (2016)
4. Tio2 Nanoparticles Enhance the Chemotherapeutic Effects of 5-Fluorouracil in Human Ags Gastric Cancer Cells Via Autophagy Blockade, Life Sciences (2020)
5. Apigenin Enhanced Radiation-Induced Apoptosis/Necrosis by Sensitization of Lncap Prostate Cancer Cells to 6 Mv Photon Beams, Cell Journal (2021)
6. Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial, Nephro-Urology Monthly (2015)
7. Cancer Incidence in Iran in 2014: Results of the Iranian National Population-Based Cancer Registry, Cancer Epidemiology (2019)
8. Development and Clinical Application of Bispecific Antibody in the Treatment of Colorectal Cancer, Expert Review of Clinical Immunology (2020)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (4)
Kazem Zendehdel (4)
Other Related Docs
9. The Epidemiology of Brain and Spinal Cord Tumors, Advances in Experimental Medicine and Biology (2023)
10. Economic Burden of Gynecological Cancers in Iran, Value in Health Regional Issues (2022)
11. Cytotoxic Effect of Iris Germanica L. Rhizomes Extract on Human Melanoma Cell Line, International Journal of Cancer Management (2021)
12. The Association Between Ultra-Processed Foods Intake and the Odds of Prostate Cancer: A Case–Control Study, Journal of Health, Population and Nutrition (2025)
13. Androgen Deprivation Therapy Use and the Risk of Heart Failure in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis, BMC Cardiovascular Disorders (2024)
14. Factors Associated With Survival of Patients With Leukemia Using Penalized Splines and Comparing That With the Cox Proportional Hazards Model, Journal of Mazandaran University of Medical Sciences (2023)
15. Expression and Clinicopathological Significance of Aoc4p, Prncr1, and Pcat1 Lncrnas in Breast Cancer, Pathology Research and Practice (2020)
16. Methylated Dna Markers of Esophageal Squamous Cancer and Dysplasia: An International Study, Cancer Epidemiology Biomarkers and Prevention (2020)
17. Qaly League Table of Iran: A Practical Method for Better Resource Allocation, Cost Effectiveness and Resource Allocation (2021)
18. The Prediction Incidence of the Three Most Common Cancers Among Iranian Military Community During 2007-2019: A Time Series Analysis, Journal of Preventive Medicine and Hygiene (2019)
19. Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride, Iranian Journal of Pharmaceutical Research (2021)
20. Increasing the Colon Cancer Cells Sensitivity Toward Radiation Therapy Via Application of Oct4–Sox2 Complex Decoy Oligodeoxynucleotides, Molecular Biology Reports (2020)
21. Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?, Frontiers in Oncology (2021)
22. Assessment of Tissue Oxidative Stress, Antioxidant Parameters, and Zinc and Copper Levels in Patients With Breast Cancer, Biological Trace Element Research (2023)
23. Population Attributable Proportion and Number of Cancer Cases Attributed to Potentially Modifiable Risk Factors in Iran in 2020, International Journal of Cancer (2023)
24. Direct and Indirect Medical Costs of Bladder Cancer in Iran, Cost Effectiveness and Resource Allocation (2023)
25. Germline Variants in Patients From the Iranian Hereditary Colorectal Cancer Registry, Cancer Cell International (2025)
26. Descriptive Epidemiology of Early-Onset Gastrointestinal Cancers in Iran, 2014-2018, Middle East Journal of Digestive Diseases (2024)
27. Quercetin As a Jak–Stat Inhibitor: A Potential Role in Solid Tumors and Neurodegenerative Diseases, Cellular and Molecular Biology Letters (2022)
28. National and Subnational Burden of Female and Male Breast Cancer and Risk Factors in Iran From 1990 to 2019: Results From the Global Burden of Disease Study 2019, Breast Cancer Research (2023)